Bel, Belgium

Time filter

Source Type

Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2013.2.4.1-1 | Award Amount: 8.10M | Year: 2013

Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of omics-based approaches, has revealed that cancer must be considered a heterogeneous disease. Historically, one-size-fits-all approaches have been standard practice in CRC treatment, but with the increased understanding of the molecular/genetic heterogeneity of CRC, it is clear that novel treatments must be developed and tested in selected subgroups to maximize the benefit of these new developments. MErCuRIC is a multicentre phase Ib/II clinical trial which will assess a novel therapeutic strategy (combined treatment of a MEK inhibitor PD-0325901 with a MET inhibitor PF-02341066) to combat metastasis, improve survival and change current clinical practice for CRC patients with KRAS mutant (MT) and KRAS wild type (WT) (with aberrant c-MET) tumours. The consortium will go beyond the current state-of-the-art by (i) employing a novel treatment strategy targeting the biology of the disease and by (ii) using next generation sequencing (NGS) and xenopatients to identify CRC patient subgroups who will maximally benefit from this novel treatment strategy.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2012.2.1.1-1-B | Award Amount: 15.82M | Year: 2012

EURenOmics will integrate several established consortia devoted to rare kidney diseases with eminent need and potential for diagnostic and therapeutic progress (i.e. steroid resistant nephrotic syndrome, membranous nephropathy, tubulopathies, complement disorders such a haemolytic uraemic syndrome, and congenital kidney malformations). The Consortium has access to the largest clinical cohorts assembled to date (collectively >10,000 patients) with detailed phenotypic information and comprehensive biorepositories containing DNA, blood, urine, amniotic fluid and kidney tissue. The project aims to (1) identify the genetic and epigenetic causes and modifiers of disease and their molecular pathways; (2) define a novel mechanistic disease ontology beyond phenotypical or morphological description; (3) develop innovative technologies allowing rapid diagnostic testing; (4) discover and validate biomarkers of disease activity, prognosis and treatment responses; and (5) develop in vitro and in vivo disease models and apply high-throughput compound library screening. For these purposes we will integrate comprehensive data sets from next generation exome and whole-genome sequencing, ChiP-sequencing, tissue transcriptome and antigen/epitope profiling, and miRNome, proteome/peptidome, and metabolome screening in different body fluids within and across conventional diagnostic categories. These data will be combined in a systems biology approach with high-resolution clinical phenotyping and findings obtained with a large array of established and novel in vitro, ex vivo and in vivo disease models (functiomics) to identify disease-associated genetic variants involved in monogenic or complex genetic transmission, disease-defining molecular signatures, and potential targets for therapeutic intervention. These efforts will converge in the development of innovative diagnostic tools and biomarkers and efficient screening strategies for novel therapeutic agents.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-IP | Phase: HEALTH.2012.2.1.1-2 | Award Amount: 15.18M | Year: 2013

The ageing of the European population represents a rapidly rising social and economic challenge. Especially cardiovascular morbidity increases with age, but unfortunately, elderly patients are often difficult to diagnose due to confounding factors, leading to uncertainties in clinical decision making with huge impact on patients outcomes. Hence, there is an unmet need for novel biomarkers for more accurate diagnosis, risk assessment, and clinical outcome prediction for both acute and chronic cardiovascular diseases in the elderly. The BestAgeing consortium aims to improve this lack of diagnostic capabilities by developing and validating innovative omics-based biomarkers particularly for elderly patients supporting healthy ageing in Europe. Our study design addresses the most frequent and severe cardiovascular diseases of elderly patients by incorporating the appropriate disease cohorts and biomaterials from European populations. We aim to develop new omics-assays to diagnose cardiovascular disease, estimate risk, and monitor the response to treatment in elderly. This is envisaged to enable a more stratified and economic delivery of medicine. We expect that BestAgeing will generate novel European medical technologies that can improve the efficacy and efficiency of our care for elderly patients, which will also impact on socioeconomic wealth in Europe.


SANTA CLARA, Calif. & NIEL, Belgium--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) and Multiplicom N.V. today announced that they have signed a definitive agreement under which Agilent will acquire Multiplicom, a leading European diagnostics company with state-of-the-art genetic testing technology and products. Multiplicom, headquartered in Niel, Belgium, develops, manufactures and commercializes molecular-diagnostic solutions, provided as kits, which enable personalized medicine. Specifically, these solutions enable clinical labs to identify the DNA variants that are associated with a genetic disease or predisposition in patients, or that may steer cancer therapy or identify congenital defects early in pregnancy. “The acquisition of Multiplicom significantly strengthens our presence in the genomics market,” said Herman Verrelst, vice president and general manager of Agilent’s Genomics Division. “Multiplicom’s products and technology help expand our target-enrichment portfolio and enhance our next-generation sequencing workflow capabilities – providing immediate scale in adjacent markets.” “Multiplicom is excited to be a part of Agilent and for the opportunity to offer our products and technology to a global customer base,” said Dirk Pollet, Multiplicom’s CEO. “We are also immensely grateful to our investors Gimv, PMV, Qbic, RMM, University of Antwerpen and VIB for their unwavering support from Day One.” Agilent is acquiring Multiplicom for approximately €68 million in cash. The acquisition is expected to be completed by mid-January, subject to local laws and regulations and customary closing conditions. Multiplicom employs about 90 people, all of whom will be offered employment opportunities with Agilent. Multiplicom N.V. develops, manufactures and commercializes molecular diagnostic solutions, provided as kits, which enable personalized medicine. Founded in 2011 as a spin-off from the University of Antwerp (Belgium) and VIB (Flanders Institute of Biotechnology), Multiplicom achieved CE-IVD certification for the BRCA MASTR Dx assay for breast and ovarian cancer predisposition in 2012. It was the first company in Europe to achieve a BRCA CE-IVD certification and it continues to develop and market quality controlled NGS-based assays. Therefore, it enables clinical laboratories to identify the DNA variants that are associated with a genetic disease or predisposition in patients, or that may steer cancer therapy or to identify congenital defects early in pregnancy. For more information, visit www.Multiplicom.com. Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. Agilent generated revenue of $4.20 billion in fiscal 2016. The company employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com. This news release contains forward-looking statements as defined in the Securities Exchange Act of 1934 and is subject to the safe harbors created therein. The forward-looking statements contained herein include, but are not limited to, statements regarding the expansion of Agilent's product portfolio and the ability to deliver broader value for customers, expansion into additional accounts and markets, the anticipated closing date of the acquisition, and the expected benefits of the acquisition to Agilent's business and operations. These forward-looking statements involve risks and uncertainties that could cause Agilent's results to differ materially from management's current expectations. Such risks and uncertainties include, but are not limited to: unforeseen changes in the demand for current and new products, technologies, and services; customer purchasing decisions and timing; satisfaction of closing conditions; and the risk that we are not able to realize the expected benefits from acquisition activities. In addition, other risks that Agilent faces in running its operations include the ability to execute successfully through business cycles; ongoing competitive, pricing and gross-margin pressures; the impact of geopolitical uncertainties and global economic conditions on our operations, our markets and our ability to conduct business; the ability to successfully introduce new products at the right time, price and mix; the ability of Agilent to successfully integrate recent acquisitions; the ability of Agilent to successfully comply with certain complex regulations; and other risks detailed in Agilent's filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q for the quarter ended July 31, 2016. Forward-looking statements are based on the beliefs and assumptions of Agilent's management and on currently available information. Agilent undertakes no responsibility to publicly update or revise any forward-looking statement. NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available on the Agilent news site at www.agilent.com/go/news.


News Article | February 21, 2017
Site: www.accesswire.com

LONDON, UK / ACCESSWIRE / February 21, 2017 / Active Wall St. announces its post-earnings coverage on Agilent Technologies, Inc. (NYSE: A). The Company announced its first quarter fiscal 2017 financial results on February 14, 2017. The scientific instrument maker reported eighth consecutive quarter of improving profitability and also raised its core revenue guidance for the year. Register with us now for your free membership at: One of Agilent Technologies' competitors within the Medical Laboratories & Research space, Quintiles IMS Holdings, Inc. (NYSE: Q), reported its Q4 and full-year 2016 financial results and issued its 2017 guidance on Tuesday, February 14, 2017. AWS will be initiating a research report on Quintiles IMS Holdings in the coming days. Today, AWS is promoting its earnings coverage on A; touching on Q. Get our free coverage by signing up to: For the period ended January 31, 2017, Agilent reported revenue of $1.07 billion, up 3.8% or 4.8% on core basis compared to revenue of $1.03 billion in Q1 FY16. The Company's revenue numbers surpassed analysts' consensus of $1.04 billion. For Q1 FY17, Agilent reported GAAP net income of $168 million, or $0.52 per share, compared to GAAP net income of $121 million, or $0.36 per share, for Q1 FY16. During the reported quarter, Agilent had intangible amortization of $31 million, acquisition and integration costs of $16 million, transformation costs of $2 million, and $2 million of other costs. Excluding these items, a pension settlement gain of $32 million and a tax benefit of $15 million, Agilent reported Q1 FY17 non-GAAP net income of $172 million, or $0.53 per share, exceeding Wall Street's expectations for earnings of $0.49 per share. Mike McMullen, Agilent's President and CEO stated in regards to the Company's results: "Our strong revenue results were driven by a return to growth in our Chemical & Energy business and higher-than-expected China growth. Overall, we are confident in the Company's prospects, and we are raising our full-year core revenue growth expectations." For Q1 FY17, Agilent reported adjusted operating margin of 21.2%, up 100 basis points from Q1 FY16, and operating cash flow of $116 million, $5 million higher than Q1 of last year. During Q1 FY17, Agilent paid $42 million in dividends and repurchased 2.5 million shares for $111 million in the reported quarter. The Company closed on $70 million Multiplicom acquisition in January 2017. For Q1 FY17, the Company's revenue of $540 million from Agilent's Life Sciences and Applied Markets Group (LSAG) grew 3% on y-o-y basis, or 4% on a core basis, with strength in Pharma, food, chemical, and energy. LSAG's operating margin for the reported quarter was 23.4%. The Company's Agilent CrossLab Group (ACG) revenue grew 6% y-o-y, or 7% on a core basis, to $363 million. Both services and consumables experienced healthy growth across all geographies. ACG's operating margin for the reported quarter was 20.3%. During Q1 FY17, Agilent's Diagnostics and Genomics Group (DGG) generated revenue of $164 million, up 4% on y-o-y and core basis, led by strength in Dako-branded products and nucleic acid solutions. The segment's operating margin totaled 14.3% for the reported quarter. On a geographical basis, Agilent reported delivering low double digit growth in Q1FY17 in China, above the Company's expectations. The Americas reported growth in mid-single digits, with strength in the United States. Europe and Japan remained flat. For FY17, Agilent expects revenue of $4.33 billion to $4.35 billion and non-GAAP earnings of $2.10 to $2.16 per share. The Company is raising the core revenue growth guidance of 4.0% to 4.5% provided in November by 25 basis points, or $11 million. The new core revenue growth guidance is therefore 4.25% to 4.75%. However, Agilent noted that the strengthening of the US dollar since its November guidance is expected to have a negative impact of about $36 million on full-year reported revenues. The Company's FY17 guidance of $825 million operating cash flow, $200 million CapEx, and buyback of $430 million for the year remained unchanged. For Q2 FY17, Agilent expects revenue in the range of $1.04 billion to $1.06 billion, where the midpoint corresponds to a core revenue growth of 3.5%. The Company's non-GAAP earnings are expected to be in the range of $0.47 to $0.49 per share for Q2 FY17, a 9% y-o-y increase at midpoint. At the closing bell, on Friday, February 17, 2017, Agilent Technologies' stock climbed 1.55%, ending the trading session at $51.63. A total volume of 2.20 million shares were traded at the end of the day, which was higher than the 3-month average volume of 2.05 million shares. In the last three months and previous twelve months, shares of the Company have advanced 12.13% and 39.41%, respectively. Moreover, the stock surged 13.32% since the start of the year. The Company's shares are trading at a PE ratio of 33.22 and have a dividend yield of 1.03%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | February 21, 2017
Site: marketersmedia.com

LONDON, UK / ACCESSWIRE / February 21, 2017 / Active Wall St. announces its post-earnings coverage on Agilent Technologies, Inc. (NYSE: A). The Company announced its first quarter fiscal 2017 financial results on February 14, 2017. The scientific instrument maker reported eighth consecutive quarter of improving profitability and also raised its core revenue guidance for the year. Register with us now for your free membership at: One of Agilent Technologies' competitors within the Medical Laboratories & Research space, Quintiles IMS Holdings, Inc. (NYSE: Q), reported its Q4 and full-year 2016 financial results and issued its 2017 guidance on Tuesday, February 14, 2017. AWS will be initiating a research report on Quintiles IMS Holdings in the coming days. Today, AWS is promoting its earnings coverage on A; touching on Q. Get our free coverage by signing up to: For the period ended January 31, 2017, Agilent reported revenue of $1.07 billion, up 3.8% or 4.8% on core basis compared to revenue of $1.03 billion in Q1 FY16. The Company's revenue numbers surpassed analysts' consensus of $1.04 billion. For Q1 FY17, Agilent reported GAAP net income of $168 million, or $0.52 per share, compared to GAAP net income of $121 million, or $0.36 per share, for Q1 FY16. During the reported quarter, Agilent had intangible amortization of $31 million, acquisition and integration costs of $16 million, transformation costs of $2 million, and $2 million of other costs. Excluding these items, a pension settlement gain of $32 million and a tax benefit of $15 million, Agilent reported Q1 FY17 non-GAAP net income of $172 million, or $0.53 per share, exceeding Wall Street's expectations for earnings of $0.49 per share. Mike McMullen, Agilent's President and CEO stated in regards to the Company's results: "Our strong revenue results were driven by a return to growth in our Chemical & Energy business and higher-than-expected China growth. Overall, we are confident in the Company's prospects, and we are raising our full-year core revenue growth expectations." For Q1 FY17, Agilent reported adjusted operating margin of 21.2%, up 100 basis points from Q1 FY16, and operating cash flow of $116 million, $5 million higher than Q1 of last year. During Q1 FY17, Agilent paid $42 million in dividends and repurchased 2.5 million shares for $111 million in the reported quarter. The Company closed on $70 million Multiplicom acquisition in January 2017. For Q1 FY17, the Company's revenue of $540 million from Agilent's Life Sciences and Applied Markets Group (LSAG) grew 3% on y-o-y basis, or 4% on a core basis, with strength in Pharma, food, chemical, and energy. LSAG's operating margin for the reported quarter was 23.4%. The Company's Agilent CrossLab Group (ACG) revenue grew 6% y-o-y, or 7% on a core basis, to $363 million. Both services and consumables experienced healthy growth across all geographies. ACG's operating margin for the reported quarter was 20.3%. During Q1 FY17, Agilent's Diagnostics and Genomics Group (DGG) generated revenue of $164 million, up 4% on y-o-y and core basis, led by strength in Dako-branded products and nucleic acid solutions. The segment's operating margin totaled 14.3% for the reported quarter. On a geographical basis, Agilent reported delivering low double digit growth in Q1FY17 in China, above the Company's expectations. The Americas reported growth in mid-single digits, with strength in the United States. Europe and Japan remained flat. For FY17, Agilent expects revenue of $4.33 billion to $4.35 billion and non-GAAP earnings of $2.10 to $2.16 per share. The Company is raising the core revenue growth guidance of 4.0% to 4.5% provided in November by 25 basis points, or $11 million. The new core revenue growth guidance is therefore 4.25% to 4.75%. However, Agilent noted that the strengthening of the US dollar since its November guidance is expected to have a negative impact of about $36 million on full-year reported revenues. The Company's FY17 guidance of $825 million operating cash flow, $200 million CapEx, and buyback of $430 million for the year remained unchanged. For Q2 FY17, Agilent expects revenue in the range of $1.04 billion to $1.06 billion, where the midpoint corresponds to a core revenue growth of 3.5%. The Company's non-GAAP earnings are expected to be in the range of $0.47 to $0.49 per share for Q2 FY17, a 9% y-o-y increase at midpoint. At the closing bell, on Friday, February 17, 2017, Agilent Technologies' stock climbed 1.55%, ending the trading session at $51.63. A total volume of 2.20 million shares were traded at the end of the day, which was higher than the 3-month average volume of 2.05 million shares. In the last three months and previous twelve months, shares of the Company have advanced 12.13% and 39.41%, respectively. Moreover, the stock surged 13.32% since the start of the year. The Company's shares are trading at a PE ratio of 33.22 and have a dividend yield of 1.03%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / February 21, 2017 / Active Wall St. announces its post-earnings coverage on Agilent Technologies, Inc. (NYSE: A). The Company announced its first quarter fiscal 2017 financial results on February 14, 2017. The scientific instrument maker reported eighth consecutive quarter of improving profitability and also raised its core revenue guidance for the year. Register with us now for your free membership at: One of Agilent Technologies' competitors within the Medical Laboratories & Research space, Quintiles IMS Holdings, Inc. (NYSE: Q), reported its Q4 and full-year 2016 financial results and issued its 2017 guidance on Tuesday, February 14, 2017. AWS will be initiating a research report on Quintiles IMS Holdings in the coming days. Today, AWS is promoting its earnings coverage on A; touching on Q. Get our free coverage by signing up to: For the period ended January 31, 2017, Agilent reported revenue of $1.07 billion, up 3.8% or 4.8% on core basis compared to revenue of $1.03 billion in Q1 FY16. The Company's revenue numbers surpassed analysts' consensus of $1.04 billion. For Q1 FY17, Agilent reported GAAP net income of $168 million, or $0.52 per share, compared to GAAP net income of $121 million, or $0.36 per share, for Q1 FY16. During the reported quarter, Agilent had intangible amortization of $31 million, acquisition and integration costs of $16 million, transformation costs of $2 million, and $2 million of other costs. Excluding these items, a pension settlement gain of $32 million and a tax benefit of $15 million, Agilent reported Q1 FY17 non-GAAP net income of $172 million, or $0.53 per share, exceeding Wall Street's expectations for earnings of $0.49 per share. Mike McMullen, Agilent's President and CEO stated in regards to the Company's results: "Our strong revenue results were driven by a return to growth in our Chemical & Energy business and higher-than-expected China growth. Overall, we are confident in the Company's prospects, and we are raising our full-year core revenue growth expectations." For Q1 FY17, Agilent reported adjusted operating margin of 21.2%, up 100 basis points from Q1 FY16, and operating cash flow of $116 million, $5 million higher than Q1 of last year. During Q1 FY17, Agilent paid $42 million in dividends and repurchased 2.5 million shares for $111 million in the reported quarter. The Company closed on $70 million Multiplicom acquisition in January 2017. For Q1 FY17, the Company's revenue of $540 million from Agilent's Life Sciences and Applied Markets Group (LSAG) grew 3% on y-o-y basis, or 4% on a core basis, with strength in Pharma, food, chemical, and energy. LSAG's operating margin for the reported quarter was 23.4%. The Company's Agilent CrossLab Group (ACG) revenue grew 6% y-o-y, or 7% on a core basis, to $363 million. Both services and consumables experienced healthy growth across all geographies. ACG's operating margin for the reported quarter was 20.3%. During Q1 FY17, Agilent's Diagnostics and Genomics Group (DGG) generated revenue of $164 million, up 4% on y-o-y and core basis, led by strength in Dako-branded products and nucleic acid solutions. The segment's operating margin totaled 14.3% for the reported quarter. On a geographical basis, Agilent reported delivering low double digit growth in Q1FY17 in China, above the Company's expectations. The Americas reported growth in mid-single digits, with strength in the United States. Europe and Japan remained flat. For FY17, Agilent expects revenue of $4.33 billion to $4.35 billion and non-GAAP earnings of $2.10 to $2.16 per share. The Company is raising the core revenue growth guidance of 4.0% to 4.5% provided in November by 25 basis points, or $11 million. The new core revenue growth guidance is therefore 4.25% to 4.75%. However, Agilent noted that the strengthening of the US dollar since its November guidance is expected to have a negative impact of about $36 million on full-year reported revenues. The Company's FY17 guidance of $825 million operating cash flow, $200 million CapEx, and buyback of $430 million for the year remained unchanged. For Q2 FY17, Agilent expects revenue in the range of $1.04 billion to $1.06 billion, where the midpoint corresponds to a core revenue growth of 3.5%. The Company's non-GAAP earnings are expected to be in the range of $0.47 to $0.49 per share for Q2 FY17, a 9% y-o-y increase at midpoint. At the closing bell, on Friday, February 17, 2017, Agilent Technologies' stock climbed 1.55%, ending the trading session at $51.63. A total volume of 2.20 million shares were traded at the end of the day, which was higher than the 3-month average volume of 2.05 million shares. In the last three months and previous twelve months, shares of the Company have advanced 12.13% and 39.41%, respectively. Moreover, the stock surged 13.32% since the start of the year. The Company's shares are trading at a PE ratio of 33.22 and have a dividend yield of 1.03%. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | November 23, 2016
Site: www.newsmaker.com.au

ReportsnReports.com adds “Global Next Generation Sequencing Market Research Report 2016” new report to its research database. The report spread across 125 pages with table and figures in it. Global Next Generation Sequencing Market Report is a professional and in-depth research report on the world's major regional market conditions of the Next Generation Sequencing industry, focusing on the main regions and the main countries (United States, Europe, Japan and China). The report introduces Next Generation Sequencing basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis, etc. Insightful predictions for the Next Generation Sequencing market for the coming few years have also been included in the report. These predictions feature important inputs from leading industry experts and take into account every statistical detail regarding the Next Generation Sequencing market. Complete report on the Next Generation Sequencing Market Research Report spread across 125 pages, profiling 15 companies and supported with 125 tables and figures is now available at @ http://www.reportsnreports.com/contacts/discount.aspx?name=761348 . #Key Manufacturers profiled in this research are Illumina, Inc., Qiagen N.V., QuantuMDx Group, Quest Diagnostics, RainDance Technologies, Inc., Response Genetics, Inc., Roche, SeqLL, LLC, Sequenta, Inc., Mayo Medical Laboratories and Mayo Clinic, MolecularMD Corporation, Multiplicom NV, DNA Electronics Ltd., DNASTAR, Inc. and Innovations Exchange Pte Ltd (INEX) no less than 15 top producers. Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins. The report focuses on global major leading Next Generation Sequencing Industry players providing information such as company profiles, product picture and specification, capacity, production, price, cost, revenue and contact information. Global Next Generation Sequencing Industry 2016 is a comprehensive, professional report delivering market research data that is relevant for new market entrants or established players. Key strategies of the companies operating in the market and their impact analysis have been included in the report. Furthermore, a business overview, revenue share, and SWOT analysis of the leading players in the Next Generation Sequencing market is available in the report. With the list of tables and figures the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market. 1 Industry Overview 2 Manufacturing Cost Structure Analysis of Next Generation Sequencing 3 Technical Data and Manufacturing Plants Analysis 4 Production Analysis of Next Generation Sequencing by Regions, Technology, and Applications 5 Sales and Revenue Analysis of Next Generation Sequencing by Regions 6 Analysis of Next Generation Sequencing Production, Supply, Sales and Market Status 2010-2016 7 Analysis of Next Generation Sequencing Industry Key Manufacturers 8 Price and Gross Margin Analysis 9 Marketing Trader or Distributor Analysis of Next Generation Sequencing 10 Development Trend of Next Generation Sequencing Industry 2016-2021 11 Industry Chain Suppliers of Next Generation Sequencing with Contact Information 12 New Project Investment Feasibility Analysis of Next Generation Sequencing 13 Conclusion of the Global Next Generation Sequencing Industry Report 2016 Some of the tables and figures provided in Global Next Generation Sequencing Market Report 2016 research report include: Table Global Capacity (Unit) of  Next Generation Sequencing by Types 2011-2016 Figure Global Capacity Market Share of  Next Generation Sequencing by Types in 2011 Figure Global Capacity Market Share of  Next Generation Sequencing by Types in 2015 Table Global Production (Unit) of  Next Generation Sequencing by Types 2011-2016 Figure Global Production Market Share of  Next Generation Sequencing by Types in 2011 Figure Global Production Market Share of  Next Generation Sequencing by Types in 2015 Table Global Revenue (M USD) of  Next Generation Sequencing by Types 2011-2016 Figure Global Revenue Market Share of  Next Generation Sequencing by Types in 2011 Figure Global Revenue Market Share of  Next Generation Sequencing by Types in 2015 Table Global and Major Manufacturers Capacity (Unit) of  Next Generation Sequencing 2011-2016 Table Global Capacity Market Share of  Next Generation Sequencing Major Manufacturers 2011-2016 Figure Global Capacity Market Share of  Next Generation Sequencing Major Manufacturers in 2011 Figure Global Capacity Market Share of  Next Generation Sequencing Major Manufacturers in 2015 Table Global and Major Manufacturers Production (Unit) of  Next Generation Sequencing 2011-2016 Table Global Production Market Share of  Next Generation Sequencing Major Manufacturers 2011-2016 Figure Global Production Market Share of  Next Generation Sequencing Major Manufacturers in 2011 Figure Global Production Market Share of  Next Generation Sequencing Major Manufacturers in 2015 Table Global and Major Manufacturers Revenue (M USD) of  Next Generation Sequencing 2011-2016 Connect us @ [email protected] with subject line “2016 Market Research Report on Global Next Generation Sequencing Industry “ and your contact details to purchase this report or get your questions answered. OR Call Us @ +1 888 391 5441. ReportsnReports.com is an online market research reports library of 500,000+ in,depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.


Grant
Agency: Cordis | Branch: FP7 | Program: CP-FP | Phase: HEALTH.2012.1.4-1 | Award Amount: 3.74M | Year: 2012

The presence of donor specific HLA antibodies is a contra-indication for renal transplantation. Highly sensitized patients accumulate and often die on the transplant waiting lists as it is almost impossible to find donors towards which they dont have antibodies. The acceptable mismatch program of Eurotransplant has shown to be an effective tool to enhance successful transplantation of highly sensitized patients. However, 35% of the patients have rare HLA phenotypes and no suitable donor can be found. HLA phenotype frequencies vary amongst European populations. Rare HLA phenotypes in one population are more frequent in other populations. The major objective of the 10 partners in this project is to analyze the feasibility and requirements for a Europe-wide acceptable mismatch program to enhance transplantation of patients with rare HLA phenotypes in their own population. Long waiting patients will be matched with virtual donors based on known HLA frequencies of different European populations and with actual donors from the different transplant organizations. If successful, the logistics will be tested by transplanting some of these patients with donors from elsewhere in Europe. Second objective is to simplify the definition of acceptable HLA mismatches. Although almost 4000 HLA class I antigens are known, only 150 polymorphic residues differentially spread over the different HLA antigens are responsible for the induction of antibodies. An innovative typing and matching strategy based on the definition of acceptable HLA epitopes will facilitate the identification of suitable donors. Third objective is to define whether antibodies against non-HLA targets on the donor endothelium affect the results of transplants in highly sensitized patients. The aims of this collaborative project are fully compatible with those required for the program Health.2012.1.4-1. In objectives 2 and 3 two partners belonging to the SME sector of the European industry are involved.


Patent
Multiplicom | Date: 2012-10-18

The invention relates to prenatal detection methods using non-invasive techniques. In particular, it relates to prenatal diagnosis of a fetal chromosomal aneuploidy by detecting fetal and maternal nucleic acids in a maternal biological sample. More particularly, the invention applies multiplex PCR to amplify selected fractions of the respective chromosomes of maternal and fetal chromosomes. Respective amounts of suspected aneuploid chromosomal regions and reference chromosomes are determined from massive sequencing analysis followed by a statistical analysis to detect a particular aneuploidy.

Loading Multiplicom collaborators
Loading Multiplicom collaborators